22 November 2013
EMA/710491/2013
Press Office

Opinions on safety variations/PSURs

Adopted at the CHMP meeting of 18-21 November 2013

Name of medicine	INN	Scope
Adcetris	brentuximab vedotin	CHMP opinion to update sections 4.4 and 4.8 of the SmPC with information related to new risk of acute pancreatitis and a warning on pulmonary toxicity.
Arzerra	ofatumumab	CHMP opinion to amend the existing warning of hepatitis B reactivation in section 4.4. of the SmPC and to add hepatitis B infection and reactivation to section 4.8 of the SmPC. Among other things, mandatory screening for HBV prior to initiating Arzerra treatment is to be included.
Dacogen	decitabine	PSUR assessment resulting in a CHMP opinion to update sections 4.4 and 4.8 of the SmPC with information on risk of infections based on the results of cumulative reviews performed by the MAH.
Efient	prasugrel	CHMP opinion to update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to optimize the instructions with regard to the timing of the loading dose of prasugrel in patients with non-ST segment elevation myocardial infarction undergoing percutaneous coronary intervention based on data from TADF (ACCOAST) Study and ALKK PCI registry (Study B008).

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8669
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Name of medicine	INN	Scope
Erbitux	cetuximab	CHMP opinion to update sections 4.1 and 5.1 of the SmPC to reflect modification of the indication to patients with established wild-type RAS (i.e. KRAS and NRAS) metastatic colorectal cancer. In addition, section 4.3 is updated to contraindicate the combination with FOLFOX in patients with mutant RAS tumours or unknown status, and relevant changes are also made to sections on posology and warnings (4.2 and 4.4).
Esmya	ulipristal	CHMP opinion to update sections 4.1, 4.2, 4.3, 4.4, 4.8 and 5.1 of the SmPC based on two completed studies which investigated the safety and efficacy of up to four 3-month treatment courses of ulipristal acetate 10 mg. The limitation to a single 3-month treatment course is to be removed with the possibility of prescribing a second 3-month treatment course.
Iclusig	ponatinib	CHMP opinion to update sections 4.2, 4.4, 4.8 of the SmPC in order to add a warning regarding the risk of developing arterial and venous thrombotic events in patients treated with Iclusig.
Invanz	ertapenem	CHMP opinion to update section 4.8 of the SmPC with the adverse event term "depressed level of consciousness".
IntronA/Pegintron/ ViraferonPeg	(pegylated) interferon alfa-2b	CHMP opinion to update sections 4.4 and 4.8 of the SmPC with the adverse event of serous retinal detachment.
Proquad Varivax	measles, mumps, rubella and varicella vaccine (live) varicella vaccine (live)	CHMP opinion to update section 4.8 of the SmPCs to include "necrotizing retinitis" based on a post-marketing safety report in an immunocompromised individual. In addition, section 4.3 of the SmPC is updated to include references to section 4.8 and vice versa.
Myozyme	alglucosidase alfa	CHMP opinion to update sections 4.4 and 4.8 of the SmPC with the clinical data available from studies AGLU03707 and AGLU03807: - section 4.4: information that treating patients with Pompe disease with immunosuppressive agents may further increase the risk of developing severe respiratory infections and vigilance is recommended. - section 4.8: information on existence of recurrent reactions consisting of flu-like illness or a combination of events such as fever, chills, myalgia, arthralgia, pain, or fatigue occurring post-infusion and lasting usually for a few days, in some patients treated with alglucosidase alfa.
Rapiscan	regadenoson	PSUR assessment resulting in a CHMP opinion to update section 4.4 of the SmPC with warnings regarding

Name of medicine	INN	Scope
		the use in patients with a recent myocardial infarction, the off label use in combination with exercise, the use in patients at risk of seizure and a warning that regadenoson may cause a worsening or recurrence of atrial fibrillation. Update of section 4.8 to clarify that, as well as causing new-onset atrial fibrillation, regadenoson may worsen or cause a recurrence of atrial fibrillation.
Rebetol/Pegintron/ ViraferonPeg	ribavirin/pegylated interferon	CHMP opinion to update of sections 4.1, 4.4, 4.8 and 5.1 of the SmPC with long-term follow-up safety and efficacy data on the durability of virologic response and growth amongst paediatric patients from study P02538, and study P01906.
Temodal	temozolomide	CHMP opinion to update sections 4.4 and 4.8 of the SmPC to include the risk of severe liver injuries including those with fatal outcome. This follows the review of a signal of hepatic failure identified by the EMA in the Eudravigilance database.
Tygacil	tigecycline	CHMP opinion to update sections 4.4 and 4.8 of the SmPC to include the most current pooled safety data in the approved indications obtained from the completed phase 3 and phase 4 studies. The clinical database is updated with safety data from 4 additional studies conducted in the approved indications.
Xarelto	rivaroxaban	CHMP opinion to update section 4.4 of the SmPC regarding the concomitant use of potent Cyp3A4/Pgp inhibitors. In addition, the following sections are also updated: - section 4.2 to introduce crushing tablets as an alternative way of administration. - section 4.5 with new data from a DDI interaction study in patients with mild moderate and severe renal impairment. - section 4.8 to include angioedema and allergic oedema.
Xeloda	capecitabine	CHMP opinion to update the following sections of the SmPC: - section 4.2 to include additional dose information on the combination with irinotecan. - sections 4.4 and 4.8 to include severe skin reactions. - section 5.1 of the SmPC to update information on XELIRI and to include information specific for XELIRI +/- bevacizumab.
Zytiga	abiraterone	PSUR assessment resulting in a CHMP opinion to update section 4.8 of the SmPC to add sepsis as a common adverse drug reaction.

Name of medicine	INN	Scope
Adenuric	febuxostat	PSUR assessment resulting in a CHMP opinion to add information on Toxic Epidermal Necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in the existing warning on serious allergic/hypersensitivity reactions in section 4.4 of the SmPC. Moreover, liver injury, drug reaction with eosinophilia and systemic symptoms, and TEN, are being added to section 4.8 of the SmPC.
Procoralan/Corlentor	ivabradine	PSUR assessment resulting in a CHMP opinion to update sections 4.3 and 4.6 of the SmPC in order to extend the current contra-indication during pregnancy and breastfeeding to women of child-bearing potential not using appropriate contraceptive measures. In addition, the description of the luminous phenomena (phosphenes) and vision blurred was added to section 4.8 of the SmPC according to information from post-marketing experience and "diplopia" and "visual impairment" were included as undesirable effects in section 4.8 of the SmPC.
Brilique	ticagrelor	PSUR assessment resulting in a CHMP opinion to update sections 4.5 and 4.7 of the SmPC in order to add warnings regarding concomitant use with the grapefruit juice (section 4.5) and dizziness in acute coronary syndrome patients taking ticagrelor (section 4.7). In addition, update to section 4.8 of the SmPC to add information regarding fatal intracranial bleedings in the postmarketing experience.